--- title: "Neumora Therapeutics (NMRA) news: reverse split and class action" url: "https://aibio.space/companies/neumora-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NMRA reverse split, class action, IPO and Nasdaq notice news: Neumora gets Nasdaq minimum bid price notice, has until November 10, 2025 to comply." --- NMRA Neumora Therapeutics, Inc. NASDAQ · United States # Neumora Therapeutics (NMRA) news NMRA reverse split, class action and IPO news Legal · 2026-08-14 ## [Neumora IPO class action over navacaprant disclosures awaits ruling on dismissal motion](https://aibio.space/news/neumora-ipo-class-action-navacaprant-disclosures-awaits-ruling/) A Securities Act suit in New York names Neumora, certain executive officers and certain underwriters. Defendants' reply on their motion to dismiss the second amended complaint is due August 24, 2026. ## Latest Neumora Therapeutics news 1. 2026-06-15 Distress [Neumora to cut workforce about 35% and end navacaprant after Phase 3 studies miss endpoints](https://aibio.space/news/neumora-cut-workforce-about-35-percent-end-navacaprant-after-phase-3/) Neumora Therapeutics is ending development of navacaprant after its two Phase 3 KOASTAL trials in major depressive disorder missed statistical significance. It cut about 35% of its workforce and amended a loan with K2 HealthVentures, and it says its cash will last into the third quarter of 2027. 2. 2025-05-16 Listings [Neumora gets Nasdaq minimum bid price notice, has until November 10, 2025 to comply](https://aibio.space/news/neumora-gets-nasdaq-minimum-bid-price-notice-has-until-november-10/) Nasdaq told Neumora Therapeutics on May 14, 2025 that it is below the $1.00 minimum bid price requirement. The company is weighing a reverse stock split, with a stockholder vote set for May 28, 2025. 3. 2025-05-16 Listings [Neumora Therapeutics gets Nasdaq notice for stock below $1.00 bid price](https://aibio.space/news/neumora-therapeutics-gets-nasdaq-notice-stock-below-1-00-bid-price/) The company has until November 10, 2025 to regain compliance. Stockholders vote on a possible reverse stock split on May 28, 2025. ## Neumora Therapeutics at a glance - **Ticker**: NMRA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $116.8 million ### Related companies - [Azitra](https://aibio.space/companies/azitra/) AMEX: AZTR - [Rezolute](https://aibio.space/companies/rezolute/) NASDAQ: RZLT - [Spyre Therapeutics](https://aibio.space/companies/spyre-therapeutics/) NASDAQ: SYRE - [AIM ImmunoTech](https://aibio.space/companies/aim-immunotech/) AMEX: AIM - [Olema Pharmaceuticals](https://aibio.space/companies/olema-pharmaceuticals/) NASDAQ: OLMA - [Rigel Pharmaceuticals](https://aibio.space/companies/rigel-pharmaceuticals/) NASDAQ: RIGL - [Corcept Therapeutics](https://aibio.space/companies/corcept-therapeutics/) NASDAQ: CORT - [Nano Mobile Healthcare](https://aibio.space/companies/nano-mobile-healthcare/) OTC: VNTH ### Also on NASDAQ - [Verastem](https://aibio.space/companies/verastem/) VSTM - [Alpha Teknova](https://aibio.space/companies/alpha-teknova/) TKNO - [Revelation Biosciences](https://aibio.space/companies/revelation-biosciences/) REVB - [BeyondSpring](https://aibio.space/companies/beyondspring/) BYSI - [Evogene](https://aibio.space/companies/evogene/) EVGN - [China SXT Pharmaceuticals](https://aibio.space/companies/china-sxt-pharmaceuticals/) SXTC ## Neumora Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$176.1 million](https://www.sec.gov/Archives/edgar/data/1885522/000119312526130388/) | [$200.9 million](https://www.sec.gov/Archives/edgar/data/1885522/000119312526130388/) | | Net income (loss) | [-$236.9 million](https://www.sec.gov/Archives/edgar/data/1885522/000119312526130388/) | [-$243.8 million](https://www.sec.gov/Archives/edgar/data/1885522/000119312526130388/) | | Cash from operations | [-$206.4 million](https://www.sec.gov/Archives/edgar/data/1885522/000119312526130388/) | [-$182.9 million](https://www.sec.gov/Archives/edgar/data/1885522/000119312526130388/) | | Cash and equivalents | [$182.5 million](https://www.sec.gov/Archives/edgar/data/1885522/000119312526350370/) | [$142.1 million](https://www.sec.gov/Archives/edgar/data/1885522/000119312526130388/) | | Short-term investments | | [$165.4 million](https://www.sec.gov/Archives/edgar/data/1885522/000119312526130388/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $116.8 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Neumora Therapeutics Did Neumora Therapeutics do a reverse stock split? Our latest story on this, dated May 16, 2025: "Neumora gets Nasdaq minimum bid price notice, has until November 10, 2025 to comply". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/neumora-gets-nasdaq-minimum-bid-price-notice-has-until-november-10/). Is there a class action against Neumora Therapeutics? Our latest story on this, dated Aug 14, 2026: "Neumora IPO class action over navacaprant disclosures awaits ruling on dismissal motion". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/neumora-ipo-class-action-navacaprant-disclosures-awaits-ruling/). When did Neumora Therapeutics go public? Our latest story on this, dated Aug 14, 2026: "Neumora IPO class action over navacaprant disclosures awaits ruling on dismissal motion". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/neumora-ipo-class-action-navacaprant-disclosures-awaits-ruling/). Has Neumora Therapeutics received a Nasdaq deficiency notice? Our latest story on this, dated May 16, 2025: "Neumora Therapeutics gets Nasdaq notice for stock below $1.00 bid price". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/neumora-therapeutics-gets-nasdaq-notice-stock-below-1-00-bid-price/). What is the ticker symbol of Neumora Therapeutics? Neumora Therapeutics, Inc. trades under the ticker NMRA on NASDAQ. Where is Neumora Therapeutics listed? Neumora Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Neumora Therapeutics? The SEC Central Index Key (CIK) for Neumora Therapeutics, Inc. is 1885522. Its filings are on SEC EDGAR. How many shares does Neumora Therapeutics have outstanding? 187,895,912 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Neumora Therapeutics listed under? Our directory records Neumora Therapeutics, Inc. under United States. What does Neumora Therapeutics do? Our directory classifies Neumora Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Neumora Therapeutics? The ISIN recorded for Neumora Therapeutics, Inc. is US6409791000. Does aibio.space cover Neumora Therapeutics? aibio.space lists Neumora Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Neumora Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Neumora Therapeutics profitable? Neumora Therapeutics, Inc. reported a net loss of $236.9 million for the fiscal year ended Dec 31, 2025, and used $206.4 million of cash in operations, per its annual report to the SEC. How much does Neumora Therapeutics spend on research and development? $176.1 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Neumora Therapeutics Members talk about Neumora Therapeutics (NMRA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Neumora Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1885522/000119312526441634/d128962d8k.htm) 2. 2026-08-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1885522/000119312526350370/nmra-20260630.htm) 3. 2026-06-15 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,2.03,2.05,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1885522/000119312526270328/d943192dex991.htm) 4. 2025-11-21 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1885522/000119312525291352/d873320d8k.htm) 5. 2025-05-30 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1885522/000119312525132307/d908298d8k.htm) 6. 2025-05-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1885522/000119312525121714/d933150d8k.htm) 7. 2025-04-29 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1885522/000095017025060084/nmra-20250429.htm) 8. 2025-04-11 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1885522/000095017025053346/nmra-20250411.htm) 9. 2025-03-03 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1885522/000095017025030401/nmra-20241231.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NMRA on TradingView](https://www.tradingview.com/symbols/NASDAQ-NMRA/). ## SEC filings and registration - **SEC name**: Neumora Therapeutics, Inc. - **CIK**: 1885522 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: NMRA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 260 ARSENAL PLACE, SUITE 1, WATERTOWN, MA, 02472 - **Phone**: (857) 760-0900 - **Shares outstanding**: 187,895,912 as of 2026-08-10 (10-Q filed 2026-08-14) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1885522/000119312526350370/nmra-20260630.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1885522/000119312526350349/nmra-20260814.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1885522/000119312526316819/nmra-20260727.htm) filed 2026-07-27 - [8-K](https://www.sec.gov/Archives/edgar/data/1885522/000119312526270328/d943192d8k.htm) filed 2026-06-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1885522/000119312526248244/d18793d8k.htm) filed 2026-05-29 - [10-Q](https://www.sec.gov/Archives/edgar/data/1885522/000119312526211825/nmra-20260331.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1885522/000119312526210310/nmra-20260507.htm) filed 2026-05-07 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1885522/000119312526161489/nmra-20260417.htm) filed 2026-04-17 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001885522), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Neumora Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NMRA, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Neumora Therapeutics, Inc. - **Ticker**: NMRA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US6409791000 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NMRA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/neumora-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Neumora Therapeutics (NMRA) news: reverse split and class action", 2026-10-31, https://aibio.space/companies/neumora-therapeutics/